Back to search

University of Ioannina

Φαρμακευτική παρέμβαση στις αιμοδυναμικές διαταραχές της κίρρωσης του ήπατος

Abstract

dc:description

Liver cirrhosis is characterized by circulatory dysfunction due to splanchnic arterial vasodilatation secondary to portal hypertension, which leads to a fall in systemic vascular resistance, hyperdynamic circulation, and sodium and water retention. From a chronological point of view, the abnormal sodium handling occurs before the activation of neurohumoral systems, such as the reninangiotensin-aldosterone system, the sympathetic nervous system, and the antidiuretic hormone, and the formation of ascites, and becomes more severe as the liver disease progresses. The administration of arterial vasoconstrictors have long been put forward in the treatment of hepatorenal syndrome, which is characterized by renal failure suggested to be mediated by extreme arterial vasodilatation and subsequent intense renal vasoconstriction. However, since arterial vasodilatation is a constant feature of cirrhosis, arterial vasoconstrictors could be of value in cirrhotic patients without hepatorenal syndrome. The aim of the studies of the present doctoral thesis was to evaluate the effects of chronic administration of oral midodrine, subcutaneous octreotide, or both as well as the effects of continuous infusion of somatostatin, bolus administration terlipressin, or both, and methylene blue on systemic hemodynamics and renal function parameters in cirrhotic patients without hepatorenal syndrome. The effects of somatostatin, terlipressin, or both, and methylene blue on portal hemodynamics were assessed in addition to the systemic hemodynamic effects. In the first study, 39 cirrhotic patients were evaluated at baseline and 7 days after administration of oral midodrine 10 mg, t.i.d. (11 without and 12 with ascites) or placebo (8 without and 8 with ascites). In the second study, 25 patients were evaluated at baseline and 11 days after administration of subcutaneous octreotide 300 pg, b.i.d. alone (n=12) or together with oral midodrine 7.5 mg, t.i.d. (n=13). In the third study, 20 patients treated with furosemide and spironolactone were included. Of them, 10 (group 1) discontinued diuretic treatment for 7 days. Thereafter, for 5 days each patient received subcutaneous octreotide 300 pg, b.i.d., in 10 of them (group 2) in addition to their usual diuretics. Data were collected while the patients received diuretics (both groups), after discontinuation ofdiuretics (group 1), and after octreotide administration (both groups). In the fourth study, 24 patients with esophageal varices were randomly assigned to receive either an intravenous infusion of a placebo (n=12) or somatostatin 250 pg/h after an initial bolus of 250 pg (n=12) for 60 min. Thereafter, each patient received an intranenous injection of terlipressin 2 mg while the intravenous infusion of either somatostatin or placebo was maintained. The patients were evaluated at baseline,60 min after placebo or somatostatin, and 30 min after terlipressin. In the fifth study, 20 patients were evaluated at baseline an during 2 concecutive 4-hr periods after the administration of methylene blue at a dose of 3 mg/ kg (n=10) or placebo (n=10). A significant increase in urine sodium excretion was noted after midodrine administration in patients without and with ascites, in line with significant increases in mean arterial pressure and systemic vascular resistance, andsignificant decreases in cardiac output and heart rate. Significant increases in glomerular filtration rate, filtration fraction, and urine volume and significant decreases in plasma renin activity and aldosterone were observed in patients with ascites. Placebo had no effect in any study group.In the second study, similarly to the results obtained in the previous study, octreotide did not improve systemic hemodynamics whereas the addition of midodrine significantly decreased cardiac output and heart rate, and increased mean arterial pressure and systemic vascular resistance. Octreotide caused a decrease in renal vascular resistance and increased renal blood flow butsignificantly reduced glomerular filtration rate. The association of midodrine to octreotide did not modify renal hemodynamics and function as compared to baseline while it caused an almost significant minor increase in renal vascular resistance and a significant minor decrease in renal blood flow as compared to octreotide alone. Consequently, a significant minor increase in glomerular filtration rate was demonstrated. The plasma values of active renin, aldosterone,and glucagon were significantly reduced in either group. In the third study, we observed a trend to increase creatinine clearance and significant reductions in plasma active renin and plasma aldosterone levels after the discontinuation of diuretics. The subsequent introduction of octreotidereduced glomerular filtration rate, although it significantly decreased plasma active renin and plasma aldosterone. In contrast, the addition of octreotide to diuretic treatment significantly increased glomerular filtration rate, urine volume and sodium excretion. The magnitudes of the decreases in plasma active renin and aldosterone produced by the combination of octreotide and diuretics were similar to those produced by octreotide alone or by the discontinuation of diuretics.In the fourth study, placebo had no effect on the patients studied. After terlipressin, cardiac output, portal vein velocity, and portal volume significantly decreased, while mean arterial pressure and systemic vascular resistance significantly increased. Fractional sodium excretion significantly increased in patients without ascites while it did not change in patients with ascites. Somatostatin significantly reduced mean arterial pressure, heart rate, cardiac output, and, in patients with ascites, sodium excretion whereas it did not alter portal hemodynamics after 60 min. The addition of terlipressin to somatostatin induced similar changes to those observed after terlipressin alone. The magnitude of increase in mean arterial pressure was significantly higher in patients receivingterlipressin alone than in those receiving somatostatin plus terlipressin, while cardiac output was conversely affected. In the fifth study, mean arterial pressure, heart rate, cardiac output, systemicvascular resistance, plasma active renin, plasma aldosterone, plasma antidiuretic hormone, serum urea, creatinine, and sodium, urinary flow rate, glomerular filtration rate, effective renal plasma flow, portal flow volume, and portal vein velocity were not modified by methylene blue or placebo. Urinary sodium excretion, fractional sodium excretion, and serum nitric oxide levels were significantly decreased 4 hr after methylene blue administration, to return toward basal levels over a further 4-hr period. The administration of midodrine for 7 days improves systemic haemodynamics and sodium excretion in non-azotemic cirrhotic patients without or with ascites. In patients with ascites, but not in those without ascites, these effects are associated with a suppression of the activity of the renin-angiotensinaldosterone system, suggesting that the increase in natriuresis is related to the improvement in the effective arterial blood volume. The administration of octreotide alone does not improve systemic hemodynamics in nonazotemic cirrhotic patients with ascites while it impairs renal function, possibly due to inappropriate direct suppression of renin-angiotensin-aldosterone axis activity. On the other hand, the addition of midodrine to chronic octreotide treatment can ameliorate the hyperdynamic circulation it counteracts the octreotide-induced renal dysfunction in these patients. In contrast to octreotide renal adverse effects when it is administered alone, adding it to diuretic treatment increases glomerular filtration rate and sodium and water excretion, mainly through suppression of the diuretic-induced overactivity of renin-aldosterone axis. In contrast to terlipressin, somatostatin alone does not improve systemic or portal hemodynamics while it does not exert an additive portal hypotensive effect in cirrhotic patients with portal hypertension compared with terlipressin alone. Compared with somatostatin, terlipressin exerts a more beneficial effect on renal sodium excretion in patients with or without ascites. Methylene blue has no effect on systemic and portal hemodynamics in cirrhotic patients with ascites. The reduction in renal sodium excretion, in the absence of changes in renal function and hemodynamics, suggests, at least partly, a direct antinatriuretic effect of methylene blue.

Degree

thesis:*
Grantor dc:publisher
University of Ioannina
Year dc:date
2006

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Kalambokis, George
  • Καλαμπόκης, Γεώργιος

Subjects

dc:subject × 20

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/21866

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Kalambokis, George; Καλαμπόκης, Γεώργιος. Φαρμακευτική παρέμβαση στις αιμοδυναμικές διαταραχές της κίρρωσης του ήπατος. University of Ioannina, 2006. http://hdl.handle.net/10442/hedi/21866